Yen Advances As U.S. Stocks Sink Ahead Of Fed Decision

By RTTNews Staff Writer   ✉   | Published:

The Japanese yen climbed against its major counterparts in the New York session on Tuesday amid risk aversion, as investors awaited the Federal Reserve's decision on interest rates and digested warning on the nation's debt ceiling impasse.

The Fed's interest rate decision is due tomorrow, with the central bank expected to deliver another rate hike of 25 basis points.

Traders will pay close attention to the accompanying statement for clues about the outlook for rates.

CME Group's FedWatch Tool is currently indicating an 87.5 percent chance the Fed will raise rates by 25 basis points and a 72.9 percent chance the central bank will subsequently leave rates unchanged in June.

Concerns about lawmakers' struggles to reach an agreement on raising the U.S. debt ceiling are also weighing on risk sentiment.

The yen advanced to 84.57 against the kiwi and 90.85 against the aussie, from its early 4-1/2-month low of 85.41 and a 2-1/2-month low of 92.43, respectively. The yen may find resistance around 80.00 against the kiwi and 87.00 against the aussie.

The yen climbed to 152.61 against the franc and 136.38 against the greenback, off its early multi-year low of 153.96 and near a 2-month low of 137.77, respectively. The currency is seen finding resistance around 144.00 against the franc and 132.00 against the greenback.

The yen appreciated to 4-day highs of 149.82 against the euro and 169.95 against the pound, up from its prior multi-year lows of 151.61 and 172.32, respectively. Next immediate resistance for the currency is seen around 145.00 against the euro and 165.00 against the pound.

The yen rose to a 4-day high of 100.06 against the loonie, reversing from an early fresh 5-month low of 101.80. On the upside, 97.00 is likely seen as its next resistance level.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Drug major Pfizer Inc. reported a profit for the first quarter that decreased 30 percent from last year, hurt by a 29 percent revenue drop amid a decline for COVID-19 products and an unfavorable impact of foreign exchange. Both adjusted earnings and quarterly revenues topped analysts' expectations. The company also reaffirmed its adjusted earnings and revenue guidance for the full-year 2023. British energy major BP Plc reported Tuesday a replacement cost profit in its first quarter, compared to last year's hefty loss, while underlying replacement cost profit was lower as last year was benefited by surge in fuel prices following Russia's invasion of Ukraine. The company also announced a further $17.5 billion share buyback. BP shares were losing around 5 percent in the morning trading The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD. It is the first drug for the control of nonregenerative anemia associated with CKD in cats. Varenzin-CA1 works by helping to increase production of erythropoietin in the kidney, which in turn stimulates the bone mar